BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17593511)

  • 1. Advances in apheresis therapy for glomerular diseases.
    Yokoyama H; Wada T; Zhang W; Yamaya H; Asaka M
    Clin Exp Nephrol; 2007 Jun; 11(2):122-127. PubMed ID: 17593511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation effects and clinical evidence of apheresis in renal diseases.
    Yokoyama H; Wada T; Furuichi K
    Ther Apher Dial; 2003 Dec; 7(6):513-9. PubMed ID: 15018237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
    [No Abstract]   [Full Text] [Related]  

  • 4. Apheresis for Kidney Disease.
    Furuichi K; Wada T
    Contrib Nephrol; 2018; 196():188-193. PubMed ID: 30041226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunomodulation with apheresis technics].
    Liebert A; Quietzsch D; Zimmermann S
    Allerg Immunol (Leipz); 1986; 32(1):5-18. PubMed ID: 2940851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Future and limits of immunohemotherapy. Great possibilities with apheresis].
    Norda R; Lundkvist I; Söderström T
    Lakartidningen; 1995 Jan; 92(3):155-60. PubMed ID: 7837849
    [No Abstract]   [Full Text] [Related]  

  • 7. The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome.
    Yokoyama H; Shimizu M; Wada T; Yoshimoto K; Iwata Y; Shimizu K; Sakai N; Furuichi K; Hisada Y; Takakuwa H; Kobayashi K
    Ther Apher; 2002 Apr; 6(2):167-73. PubMed ID: 11982960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional apheresis therapies: a review.
    Ward DM
    J Clin Apher; 2011; 26(5):230-8. PubMed ID: 21882233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quo vadis haemapheresis. Current developments in haemapheresis.
    Borberg H
    Transfus Apher Sci; 2006 Feb; 34(1):51-73. PubMed ID: 16412691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinogen reconstitution after therapeutic apheresis: Comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption.
    Jouve T; Marlu R; Naciri Bennani H; Noble J; Chevallier E; Motte L; Imerzoukene F; Malvezzi P; Rostaing L
    J Clin Apher; 2021 Aug; 36(4):574-583. PubMed ID: 33783856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apheresis to treat systemic vasculitis.
    Moussi-Frances J; Sallée M; Jourde-Chiche N
    Joint Bone Spine; 2018 Mar; 85(2):177-183. PubMed ID: 28602810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic apheresis for renal diseases.
    Harada T; Miyazaki M; Ozono Y; Sasaki O; Shioshita K; Kohno S; Nishikido M; Saito Y; Taguchi T
    Ther Apher; 1998 Aug; 2(3):193-8. PubMed ID: 10227769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic apheresis in kidney diseases: an updated review.
    Chen YY; Sun X; Huang W; He FF; Zhang C
    Ren Fail; 2022 Dec; 44(1):842-857. PubMed ID: 35723077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apheresis therapy in Guillain-Barré syndrome].
    Nagayama H; Katayama Y
    Nihon Rinsho; 2008 Jun; 66(6):1195-9. PubMed ID: 18540370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for planning a therapeutic apheresis procedure.
    Shelat SG
    Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions].
    Haris A; Arányi J; Braunitzer H; Kálmán E; Merán Z; Soltész M; Polner K
    Orv Hetil; 2011 Jul; 152(28):1110-9. PubMed ID: 21712172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is apheresis still a useful tool in the treatment of nephrological diseases?].
    Santoro A
    G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasma exchange using filtration. Experience at the apropos of 21 patients].
    Simon P; Ang KS; Menault M; Bombail D; Vaucel J; Guezennec M; Boivin M; Bonn F
    Rev Fr Transfus Immunohematol; 1981 Dec; 24(6):671-90. PubMed ID: 6800023
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic apheresis for renal disorders.
    Sanchez AP; Ward DM
    Semin Dial; 2012; 25(2):119-31. PubMed ID: 22428811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.